The SPIZ study: rationale and protocol of a randomized controlled trial to optimize interdisciplinary care of patients following cellular therapy through a digitally supported, cross-regional and cross-sectoral care model
Annals of Hematology · 2026
DOI: 10.1007/s00277-026-07290-9 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Annals of Hematology, 2026. Verfasst von Martin M K Schneider und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Hematologic Neoplasms, Patient Care Team, Immunotherapy, Adoptive. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Carl Gustav Carus Dresden an der Technischen Universität Dresden.
Abstract (Originalsprache)
Allogeneic hematopoietic cell transplantation (alloHCT) and chimeric antigen receptor T (CAR T)-cell therapy represent established therapeutic modalities for selected hematologic malignancies but are associated with substantial morbidity, high healthcare costs, and a considerable risk of severe complications, including death. This necessitates specialized and continuous post-treatment care, which is currently insufficiently standardized and still largely delivered predominantly through in-person and nonintegrated processes. We aimed to develop a comprehensive and innovative post-treatment care program for patients after alloHCT and CAR T-cell therapy based on an interdisciplinary, digitally supported, cross-regional and, cross-sectoral approach, and to evaluate its effectiveness in a randomized controlled trial (RCT). Developed by a multidisciplinary team, the intervention involves case managers and home visits by onco nurses, supported by digital components. These include patient-reported monitoring of vital signs and symptoms via a mobile application, video consultations, and virtual case conferences with community-based hematologists. The evaluation of effectiveness includes both quantitative outcomes, such as mortality and rehospitalization rates, and qualitative data derived from semi-structured interviews. The required ethics approvals were obtained in due time, and the three study centers were successfully initiated in 2024. As of January 2026, recruitment has been completed, and a total of 306 patients were successfully enrolled and randomized in a 1:1 ratio to receive either the SPIZ intervention or routine care. Funded and supported by the Federal Joint Committee (G-BA), a positive evaluation could facilitate the integration of the proposed care model into routine clinical practice, thereby strengthening post-treatment care for patients undergoing cellular therapy across Germany.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
- Center for Evidence-Based Healthcare, Faculty of Medicine, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
- Städtisches Klinikum Dresden, Dresden, Germany.
- Directorate Nursing, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
- Private Practice Hematology and Oncology, Dresden, Germany.
- Department of Medicine I, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg im Breisgau, Germany.
Förderung
- Universitätsklinikum Carl Gustav Carus Dresden an der Technischen Universität Dresden
Zitieren
APA
Schneider, M. M. K., Müller, G., Herbst, S., Slesaczeck, J., Schmädig, R., Schmidt, F., Illmer, T., Leppla, L., Valenta, S., De Geest, S., Teynor, A., Wolfien, M., Ernst, A., Bischof, L., Schmitt, J., Hänel, M., Metzeler, K. H., Platzbecker, U., Vučinić, V., …, & Egger-Heidrich, K. (2026). The SPIZ study: rationale and protocol of a randomized controlled trial to optimize interdisciplinary care of patients following cellular therapy through a digitally supported, cross-regional and cross-sectoral care model. Annals of Hematology. https://doi.org/10.1007/s00277-026-07290-9
Vancouver
Schneider MMK, Müller G, Herbst S, Slesaczeck J, Schmädig R, Schmidt F, et al. The SPIZ study: rationale and protocol of a randomized controlled trial to optimize interdisciplinary care of patients following cellular therapy through a digitally supported, cross-regional and cross-sectoral care model. Annals of Hematology. 2026. doi:10.1007/s00277-026-07290-9
BibTeX
@article{Schneider2026,
author = {Schneider, Martin M K and Müller, Gabriele and Herbst, Sabrina and Slesaczeck, Julia and Schmädig, Roman and Schmidt, Franziska and Illmer, Thomas and Leppla, Lynn and Valenta, Sabine and De Geest, Sabina and Teynor, Alexandra and Wolfien, Markus and Ernst, Alice and Bischof, Lara and Schmitt, Jochen and Hänel, Mathias and Metzeler, Klaus H and Platzbecker, Uwe and Vučinić, Vladan and Schetelig, Johannes and Bornhäuser, Martin and Middeke, Jan Moritz and Egger-Heidrich, Katharina},
title = {The SPIZ study: rationale and protocol of a randomized controlled trial to optimize interdisciplinary care of patients following cellular therapy through a digitally supported, cross-regional and cross-sectoral care model},
journal = {Annals of Hematology},
year = {2026},
doi = {10.1007/s00277-026-07290-9}
}
EUVIMED